Greiner Bio-One GmbH - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Greiner Bio-One GmbH


Greiner Bio-One GmbH

Greiner Bio-One is specialised in the development, production and distribution of plastic laboratory products. The company is a technology partner for universities, hospitals, research institutes and the diagnostic, pharmaceutical and biotechnology industries as well.

Greiner Bio-One GmbH is a division of Greiner Bio-One International AG, based in Kremsmuenster (Austria). Today Greiner Bio-One International AG generates a turnover of 364 million euros. It has over 1,700 employees and operates globally with 24 subsidiaries and numerous distributors in more than 100 countries.

Greiner Bio-One is a leading supplier of special products for cell cultures and microplates for high-throughput screening and a developer of innovative biochips and sample collection systems. The company performs contract work from the pharmaceutical industry, the diagnostic and medical sectors. Greiner Bio-One uses injection moulding to produce a whole range of customised plastic platforms for the life sciences sector and offers the complete product development and production process from the idea through to the finished product. The company produces small and large series, undertakes customer-specific branding and can call on production facilities in Europe, the U.S. and Asia.

Visit us at CPhI/ICSE/P-MEC Hall and stand number: Hall 4.1, Booth No. 41H09

Greiner Bio-One GmbH

Bad Haller Strasse 32, 4550 Kremsmuenster, Austria

Telephone: +43 7583 67910       Fax:  +43 7583 6318

E-mail: office@at.gbo.com

Website: www.gbo.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here